We are somewhat surprised to see Guidant's board support Johnson Johnson's offer. Recall that this is the same company that thought Guidant was only worth 63 a few weeks ago. Could it just be a strategy for Johnson Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson Johnson's offer.